Using ULT to Achieve Target Serum Urate Levels Linked to Lower Fracture Risk in Gout
Researchers evaluated effect of lowering serum urate levels to a target level on fracture risk among patients with gout.
Researchers evaluated effect of lowering serum urate levels to a target level on fracture risk among patients with gout.
Researchers studied the effect of colchicine on cardiovascular outcomes among patients with gout with and without coronary artery disease.
Researchers sought to determine the predictive value of mean platelet volume as a marker for cancer outcomes.
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.
An MMAI model can accurately predict long-term outcomes in patients with high-risk prostate cancer, a study suggests.
A new risk stratification model can identify patients with stage I seminoma who have a high risk of relapse, according to researchers.
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
Adding talazoparib to first-line treatment with enzalutamide improves radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, results of the TALAPRO-2 trial suggest.